10-Q quarterly report · filed Nov 6, 2026

10x Genomics, Inc. (TXG) Q3 2026 10-Q Quarterly Report

Short answer

10x Genomics, Inc. (TXG) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $151M (up 1.1% year over year) with net income of −$19M.

Q3 2026 key financials · XBRL

Revenue
$151M
+1.1% YoY · −0.2% QoQ
Net income
−$19M
+29.3% YoY · −8.3% QoQ
Operating margin
-10.7%
Gross margin
75.0%
EPS (diluted)
−$0.15
+31.8% YoY · −7.1% QoQ

Source: XBRL data from the 10x Genomics, Inc. (TXG) Q3 2026 10-Q on SEC EDGAR. USD.

10x Genomics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $150.7M, up $1.7M YoY, or 1%
  • Gross margin 75% vs 67% YoY, driven by lower inventory write-downs and product mix
  • Best segment: Single Cell consumables $93.1M, up $0.6M; worst: Spatial instruments $3.1M, down $4.0M
  • Cash and securities $575.7M, up $52.3M from December 31, 2025; nine-month operating cash flow $58.9M vs $95.3M
  • Outlook: fourth-quarter gross margin expected lower due to product mix; operating losses expected for the foreseeable future

Risk Factors

  • Newly added risk, AI Technologies: 2026 Sentira launch and third-party foundation-model dependencies introduced validation, data security and regulatory uncertainties
  • Most materially updated risk, Atera transition: shipments began September 2026, with Xenium and Visium revenue declines and expected margin pressure from instrument-heavy sales
  • Regulatory risk, clinical expansion: CLIA certification and California licensure required before patient testing, with inspections and validation potentially delaying launch
  • Market risk, research funding: NIH terminated approximately 700 grants totaling more than $2.4 billion in March 2025, pressuring customer purchases
  • Financial risk, currency exposure: approximately 27% of sales denominated in non-U.S. currencies, without a current hedging program

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other 10x Genomics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.